CURE bleeding criteria: Difference between revisions
No edit summary |
m Bot: Removing from Primary care |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Bleeding}} | ||
{{CMG}} | {{CMG}} | ||
==CURE Clinical Trials:== | ==CURE Clinical Trials:== | ||
The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial | |||
Clopidogrel In [[Unstable Angina]] To Prevent Recurrent Ischemic Events<ref name="pmid16908769">{{cite journal| author=Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S| title=Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. | journal=Circulation | year= 2006 | volume= 114 | issue= 8 | pages= 774-82 | pmid=16908769 | doi=10.1161/CIRCULATIONAHA.106.612812 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16908769 }} </ref> | |||
{{cquote| | {{cquote| | ||
*'''Major Bleeding''' | |||
*'''Major | Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial [[hypotension]] requiring the use of | ||
Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of | |||
intravenous inotropic agents) | intravenous inotropic agents) | ||
Hemoglobin decrease ≥5 g/dL or required ≥4 U of blood | Hemoglobin decrease ≥5 g/dL or required ≥4 U of blood | ||
| Line 23: | Line 19: | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Medical emergencies]] | [[Category:Medical emergencies]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Needs overview]] | |||
[[ | |||
Latest revision as of 21:11, 29 July 2020
|
Bleeding Microchapters |
|
Treatment |
|---|
|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
|
Perioperative Bleeding |
|
CURE bleeding criteria On the Web |
|
American Roentgen Ray Society Images of CURE bleeding criteria |
|
Risk calculators and risk factors for CURE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
CURE Clinical Trials:
The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial
Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events[1]
| “ |
Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of intravenous inotropic agents) Hemoglobin decrease ≥5 g/dL or required ≥4 U of blood Other major bleeding Transfusion of 2–3 U, intraocular
Led to discontinuation of study drug |
” |
References
- ↑ Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006). "Adverse impact of bleeding on prognosis in patients with acute coronary syndromes". Circulation. 114 (8): 774–82. doi:10.1161/CIRCULATIONAHA.106.612812. PMID 16908769.